ArticleDiving and hyperbaric medicine2025
Healing fragile bones: a case report on hyperbaric oxygen therapy in pycnodysostosis.
Article in Diving and hyperbaric medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pycnodysostosis is a rare lysosomal storage disorder characterised by short stature, craniofacial dysmorphisms, dental anomalies, and increased bone fragility due to osteoclast dysfunction caused by cathepsin K gene mutations. This case report describes a 43-year-old female pycnodysostosis patient with recurrent subtrochanteric fractures and delayed bone healing following multiple surgical interventions, including femoral osteotomy and bone grafting. Despite these efforts, bony union was not achieved. The patient underwent 39 sessions of hyperbaric oxygen therapy (HBOT), administered at 243.2 kPa for 120 minutes daily, five days per week. Post-treatment radiographs revealed significant fracture healing, with improvements continuing one month after therapy. Visual analogue pain scores decreased from 4 to 1, and quality of life (SF-36) improved. HBOT enhances tissue oxygenation, stimulating osteogenesis, neovascularization, and immune responses, while optimising osteoclast function, making it a promising treatment for pycnodysostosis-related fracture complications. Although ideal, a controlled trial of HBOT in this rare disorder is probably unachievable. Nevertheless, this report highlights HBOT as a potentially useful adjunctive treatment for enhancing healing of refractory fractures in pycnodysostosis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.